Description

Enoxaparin Solution for Injections 10000 anti-Cha IU/ml. 0.2 ml Syringe

Ingredients

Enoxaparin is the active ingredient in this solution for injections. Each milliliter contains 10000 anti-Xa IU of enoxaparin.

Dosage

The usual dosage of enoxaparin for preventing blood clots is based on weight and medical condition. It is typically injected under the skin once or twice a day. Always follow the dosage instructions provided by your healthcare provider.

Indications

Enoxaparin is indicated for the prevention of deep vein thrombosis (DVT) which may lead to pulmonary embolism in patients undergoing certain surgeries or who are immobile for extended periods.

Contraindications

Do not use enoxaparin if you have a history of heparin-induced thrombocytopenia or if you are allergic to any of the ingredients in the product. Consult your doctor before use.

Directions

Administer the injection exactly as directed by your healthcare provider. Clean the injection site and inject the medication under the skin as instructed. Do not self-inject unless you are trained on how to properly administer the injection.

Scientific Evidence

Enoxaparin, a low molecular weight heparin, has been extensively studied for its efficacy in preventing blood clots. Research has shown that enoxaparin is effective in reducing the risk of DVT and pulmonary embolism in high-risk patients, such as those undergoing orthopedic surgery or with acute medical conditions.

Additional Information

It is important to monitor for signs of bleeding while using enoxaparin, as it is an anticoagulant medication. Inform your healthcare provider of any unusual bleeding or bruising. Store the medication as directed and dispose of used syringes properly.

Pharmacological Effects

Enoxaparin works by inhibiting the activity of certain clotting factors in the blood, thereby preventing the formation of harmful blood clots. It specifically targets factor Xa, which plays a key role in the coagulation cascade. By blocking factor Xa, enoxaparin helps maintain normal blood flow and reduces the risk of clot formation.

Clinical Trials and Comparative Effectiveness

Clinical trials have demonstrated the efficacy of enoxaparin in preventing thromboembolic events in various patient populations. Compared to unfractionated heparin, enoxaparin has shown similar efficacy with a more predictable anticoagulant response and a lower risk of heparin-induced thrombocytopenia. Studies have also highlighted the convenience of enoxaparin’s dosing regimen, making it a preferred choice in many clinical settings.

References:
– Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep;126(3 Suppl):188S-203S. doi: 10.1378/chest.126.3_suppl.188S.

– Turpie AG, Bauer KA, Eriksson BI, Lassen MR; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002 Jun 24;162(12):1833-40. doi: 10.1001/archinte.162.12.1833.